Herceptin Hylecta

Digital Pharmacist

The RxWiki Digital Pharmacist stamp of approval lets you know that this content has been created and reviewed by a licensed pharmacist.

Herceptin Hylecta is used to treat certain types of breast cancers. This medication can be used alone or in combination therapy.

Herceptin Hylecta Overview

Reviewed: March 25, 2019
Updated: 

Herceptin Hylecta is a prescription medication used to treat certain types of breast cancers.

Herceptin Hylecta is a single product containing 2 medications: trastuzumab and hyaluronidase-OYSK. Trastuzumab belongs to a group of drugs called monoclonal antibodies, which help stop the growth of cancer cells. Hyaluronidase helps the drug to enter the site of the cancer and be most effective. 

This medication is available in an injectable form to be given into the skin (subcutaneously) by a healthcare professional.

Common side effects of Herceptin Hylecta include fatigue, joint pain and diarrhea.

How was your experience with ?

First, a little about yourself

Tell us about yourself in a few words?

What tips would you provide a friend before taking ?

What are you taking for?

Choose one
  • Other

How long have you been taking it?

Choose one
  • Less than a week
  • A couple weeks
  • A month or so
  • A few months
  • A year or so
  • Two years or more

How well did work for you?

Did you experience many side effects while taking this drug?

How likely would you be to recommend to a friend?

Herceptin Hylecta Drug Class

Back to Top

Herceptin Hylecta is part of the drug class:

Herceptin Hylecta FDA Warning

Back to Top

FDA Warning

HERCEPTIN HYLECTA administration can result in sub-clinical and clinical cardiac failure. The incidence and severity was highest in patients receiving HERCEPTIN HYLECTA with anthracycline-containing chemotherapy regimens.

Evaluate left ventricular function in all patients prior to and during treatment with HERCEPTIN HYLECTA. Discontinue HERCEPTIN HYLECTA treatment in patients receiving adjuvant therapy and withhold HERCEPTIN HYLECTA in patients with metastatic disease for clinically significant decrease in left ventricular function

Pulmonary Toxicity

HERCEPTIN HYLECTA administration can result in serious and fatal pulmonary toxicity. Symptoms usually occur during or within 24 hours of HERCEPTIN HYLECTA administration. Discontinue HERCEPTIN HYLECTA for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome. Monitor patients until symptoms completely resolve

Embryo-Fetal Toxicity

Exposure to HERCEPTIN HYLECTA during pregnancy can result in oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise patients of these risks and the need for effective contraception

Exacerbation of chemotherapy-induced neutropenia has also occurred

Hypersensitivity and severe Administration-Related Reactions (ARRs) including anaphylaxis, have been reported with HERCEPTIN HYLECTA. Serious and fatal reactions have been reported after treatment with intravenous trastuzumab products